Aluminum is an experimentally demonstrated neurotoxin and the most commonly used
vaccine adjuvant. Despite almost 90 years of widespread use of aluminum adjuvants …

We have examined the neurotoxicity of aluminum in humans and animals under various
conditions, following different routes of administration, and provide an overview of the …

Autism spectrum disorders (ASD) are serious multisystem developmental disorders and an
urgent global public health concern. Dysfunctional immunity and impaired brain function are …

Aluminium adjuvants remain the most widely used and effective adjuvants in vaccination
and immunotherapy. Herein, the particle size distribution (PSD) of aluminium oxyhydroxide …

We reviewed the three toxicokinetic reference studies commonly used to suggest that
aluminum (Al)-based adjuvants are innocuous. A single experimental study was carried out …

FDA regulations require safety testing of constituent ingredients in drugs (21 CFR 610.15).
With the exception of extraneous proteins, no component safety testing is required for …

The aluminium compounds, originally identified as adjuvants over 70 years ago, remain
unique in their widespread application to human vaccines. Given this history, it is surprising …

Aluminum (Al) salt-based adjuvants are present in a large variety of licensed vaccines and
their use is widely considered for formulations in clinical trials. Although the regulatory …

Aluminum-containing adjuvants have been used for over 90 years to enhance the immune
response to vaccines. Recent work has significantly advanced our understanding of the …

For almost a century, aluminum (Al) in the form of Al oxyhydroxide (a crystalline compound),
Al hydroxyphosphate (an amorphous Al phosphate hydroxide), Al phosphate, and Al …